Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
surufatinib + standard chemotherapy
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy involves surufatinib, an oral small-molecule tyrosine kinase inhibitor, administered alongside standard chemotherapy regimens (either Etoposide plus Carboplatin or Capecitabine plus Temozolomide). Surufatinib targets vascular endothelial growth factor receptors (VEGFR 1-3), fibroblast growth factor receptor 1 (FGFR1), and colony-stimulating factor 1 receptor (CSF-1R), thereby inhibiting angiogenesis and modulating the tumor immune microenvironment. The chemotherapy components provide cytotoxic effects through DNA alkylation (carboplatin, temozolomide), topoisomerase II inhibition (etoposide), or antimetabolite activity (capecitabine). This specific combination is being evaluated by Shanghai Chest Hospital as a first-line treatment for patients with pulmonary neuroendocrine tumors to determine if the addition of chemotherapy enhances the efficacy of surufatinib monotherapy.
- Other names
- surufatinib + standard chemotherapy-Shanghai Chest Hospital-pulmonary neuroendocrine tumorsurufatinib + ECsurufatinib + CAPTEMsurufatinib + etoposide + carboplatinsurufatinib + capecitabine + temozolomide
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)CSF1R (Macrophage colony-stimulating factor receptor)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on surufatinib + standard chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on surufatinib + standard chemotherapy.